JP2022527189A5 - - Google Patents

Info

Publication number
JP2022527189A5
JP2022527189A5 JP2021557924A JP2021557924A JP2022527189A5 JP 2022527189 A5 JP2022527189 A5 JP 2022527189A5 JP 2021557924 A JP2021557924 A JP 2021557924A JP 2021557924 A JP2021557924 A JP 2021557924A JP 2022527189 A5 JP2022527189 A5 JP 2022527189A5
Authority
JP
Japan
Prior art keywords
fgfr3
gene mutations
fgfr
fgfr gene
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557924A
Other languages
English (en)
Japanese (ja)
Other versions
JP7747521B2 (ja
JP2022527189A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025166 external-priority patent/WO2020205493A1/en
Publication of JP2022527189A publication Critical patent/JP2022527189A/ja
Publication of JP2022527189A5 publication Critical patent/JP2022527189A5/ja
Priority to JP2025072308A priority Critical patent/JP2025156297A/ja
Application granted granted Critical
Publication of JP7747521B2 publication Critical patent/JP7747521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557924A 2019-03-29 2020-03-27 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 Active JP7747521B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072308A JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166428 2019-03-29
EP19166428.3 2019-03-29
EP19188971.6 2019-07-30
EP19188971 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072308A Division JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022527189A JP2022527189A (ja) 2022-05-31
JP2022527189A5 true JP2022527189A5 (cg-RX-API-DMAC7.html) 2023-04-03
JP7747521B2 JP7747521B2 (ja) 2025-10-01

Family

ID=70296138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557924A Active JP7747521B2 (ja) 2019-03-29 2020-03-27 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤
JP2025072308A Pending JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072308A Pending JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Country Status (15)

Country Link
US (1) US12691112B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946341A1 (cg-RX-API-DMAC7.html)
JP (2) JP7747521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210145211A (cg-RX-API-DMAC7.html)
CN (1) CN113645974A (cg-RX-API-DMAC7.html)
AU (1) AU2020253827B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019446A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130460A1 (cg-RX-API-DMAC7.html)
IL (1) IL286729A (cg-RX-API-DMAC7.html)
JO (1) JOP20210266A1 (cg-RX-API-DMAC7.html)
MA (1) MA55522A (cg-RX-API-DMAC7.html)
MX (1) MX2021011926A (cg-RX-API-DMAC7.html)
PH (1) PH12021552342A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109902SA (cg-RX-API-DMAC7.html)
WO (1) WO2020205493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12277100B2 (en) * 2019-09-12 2025-04-15 Life Spectacular, Inc. Maintaining user privacy of personal, medical, and health care related information in recommendation systems
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
KR20210064274A (ko) 2018-09-21 2021-06-02 얀센 파마슈티카 엔.브이. 담관암종의 치료
BR112021015686A2 (pt) 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
US20220175768A1 (en) 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Similar Documents

Publication Publication Date Title
Lin et al. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study
Aapro et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
JP2022527482A5 (cg-RX-API-DMAC7.html)
TW201615221A (zh) 炎症用藥臨床新應用
JP2023113650A5 (cg-RX-API-DMAC7.html)
Abdallah et al. The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial
CN107308141B (zh) 石斛酚在制备预防和治疗动脉粥样硬化药物中的应用
EP4313043A1 (en) Treatment of hidradenitis suppurativa with orismilast
Klein et al. Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study
JP2022521173A5 (cg-RX-API-DMAC7.html)
Cornu et al. No effect of a homoeopathic combination of Arnica montana and Bryonia alba on bleeding, inflammation, and ischaemia after aortic valve surgery
JP2023513298A5 (cg-RX-API-DMAC7.html)
Sarzi-Puttini et al. Clinical benefits of ibuprofen arginine: a narrative review
Kalogirou et al. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
EP0074426B1 (en) Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
Barr et al. Cation metabolism during propofol sedation with and without EDTA in patients with impaired renal function
CN115645395B (zh) Myls22在制备用于治疗急性肝损伤疾病药物中的应用
CN110179773A (zh) 石斛酚在制备预防和治疗慢性肾小球疾病药物中的应用
WILSON Dialysis and psoriasis
JP2023542296A5 (cg-RX-API-DMAC7.html)
AU2024235111B2 (en) 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain
Hernández-Cruz et al. OP0123 Safety profile of JAK-inhibitors versus TNF-inhibitors in real-world clinical practice: data from a multicenter register
Robson et al. Dialysis in scleroderma
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
Li et al. ABS1104 Efficacy and Safety of Tofacitinib Combined with Iguratimod in the Treatment of Rheumatoid Arthritis Patients with Poor Response to Csdmards: A Multicenter, Prospective, Cohort Study